Danaher Corporation (DHR)
Health Care · Diversified life sciences, diagnostics, and industrial instrumentation · NYSE
Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally.
What Danaher Corporation does
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through a diversified portfolio of science and technology-based businesses, focusing on life sciences, diagnostics, and environmental and applied solutions. Its products are used extensively in research, laboratory, and production environments globally.
Themes: Clinical diagnostics, Life sciences research, Water quality and environmental monitoring, Product identification / track-and-trace, Dental/orthodontic equipment, Industrial instrumentation
Fundamentals
- Price$215.11 as of 2026-08-24 close
- Market cap$151.2B as of 2026-08-24
- 1-year return+1.6% 2025-08-22 close $211.80 → 2026-08-24 close $215.11
- P/E38.19 as of 2026-08-24
- Net margin+15.9% as of 2026-08-24
- Gross margin+58.6% as of 2026-08-24
- ROE+7.7% as of 2026-08-24
- Debt / equity0.51 as of 2026-08-24
- Revenue growth (YoY)+4.6% as of 2026-08-24
- Revenue CAGR (3y)-2.7% SEC XBRL
- Beta0.77 as of 2026-08-24
- Last reported earnings2026-07-21 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.5%; pays a dividend.
How DHR compares in its sector
- price-to-earnings ratiomiddle range 191 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldbottom 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DHR is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
49.9 #781 of 1,704 scored · #136 of 240 in Health Care
Trend 67th: the price is 12% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; volume and participation 61st: it gapped 3.3% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 50th: a fresh 20-day high. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, DHR's dividend was covered by reported results (earnings payout 24%, free-cash-flow payout 17%). This describes past coverage, not a forecast.
- Earnings payout24% dividends / net income
- Free-cash-flow payout17% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Danaher Corporation looks technically
Danaher Corporation (DHR) is trading 7.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 99 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-02-11, pushing above its recent trading range.
Trend
8
| Distance from the 200-day | it is trading 7.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $195.48 | $195.48 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $203.43 | $203.43 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 99 trading days ago — a "death cross", a bearish long-term signal | 99 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 7.6% above | +7.6% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 19.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30) | 68.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($192.99 to $220.63) — its "stochastic" reading is 94 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 93.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $242.75 | $242.75 |
|---|---|---|
| From the 52-week high | it is 9.8% below its 52-week high (its highest price of the past year) | -9.8% |
| Above the 52-week low | it is 36.0% above its 52-week low (its lowest price of the past year) | +36.0% |
| Below the 52-week high | it is 9.8% below its highest point of the past year | 9.8% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-02-11, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-02-11, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $296.06 (set on 2021-09-10) | $296.06 |
| Given back of the 52-week move | over the past year its closes ranged ($161.91 to $242.05), and it has recovered well over two thirds of its fall from last year’s high — 71% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $211.44 to $214.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 71.0% |
| From the all-time high | it is 26.1% below its all-time high | -26.1% |
| Nearest price level | it is trading 1.1% below a resistance level at $221.28 — a price it turned at twice since 2025-10-03, most recently on 2025-12-17. Since 2024-08-21 it has 8 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.1% |
| All-time low | its lowest closing price on record is $3.28 (set on 1997-04-02) | $3.28 |
| Above the all-time low | it is 6581.4% above its all-time low | +6,581% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.91 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.91 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $189.42 and $216.30 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $189.42 – $202.86 – $216.30 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 2.2 daily ranges above its 200-day average price (7.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.86× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Open gap | it gapped 3.3% above the previous close 21 sessions ago and has not traded back through the level it left behind at 179.14 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.3% |
| Gap filled | a 2.2% gap up opened on 2026-07-28 has been "filled" 17 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 17 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +9.66% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 19.9 percentage points (the stock gained 22.3% while the market gained 2.3%) | +19.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 23.2 percentage points (the stock gained 26.3% while the market gained 3.1%) | +23.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 6.6 percentage points (the stock gained 4.5% while the market gained 11.1%) | -6.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 13.1 percentage points (the stock gained 7.3% while the market gained 20.5%) | -13.2% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.8% of the share price. | +13.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $195.90 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +11.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% above the average price paid since it last reported on 2026-07-21 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $195.10 — a volume-weighted average of daily closes over 24 sessions, not a true tick-by-tick VWAP. | +12.2% |
Price levels it has turned at before
DHR last closed at $218.85 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $221.28 | Resistance | 1.1% above the last close | turned there twice · 2025-10-03 to 2025-12-17 |
| $214.80 | Support | 1.9% below the last close | turned there four times · 2025-02-21 to 2025-08-20 |
| $227.30 | Resistance | 3.9% above the last close | turned there five times · 2024-11-18 to 2026-01-13 |
| $207.44 | Support | 5.2% below the last close | turned there 9 times · 2025-04-23 to 2026-08-10 |
| $233.05 | Resistance | 6.5% above the last close | turned there four times · 2025-01-14 to 2025-12-12 |
| $201.74 | Support | 7.8% below the last close | turned there six times · 2025-03-04 to 2026-04-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 23 analysts
- Mean price target$227.96 range $195.00 – $310.00; median $230.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DHR
- Consensus EPS estimate$1.92 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Foreign currency headwinds affecting reported results and competitive positioning in international markets","Acquired intangible assets of $21.4 billion and goodwill of $47.4 billion expose the company to impairment risk if acquisitions underperform","Rising interest expenses ($170 million in H1 2026) due to increased debt levels following acquisitions, impacting profitability"]
What changed in the latest 10-Q
AI-assisted comparison of DHR's 10-Q filed 2026-04-21 against the prior one filed 2025-10-21.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'pending acquisition of Masimo Corporation, which is further described in Note 2' in the forward-looking statements section (newer filing 2026-04-21)
- Specific mention of 'recent escalation of conflict in the Middle East has heightened geopolitical instability and economic uncertainty' in Business and Strategic Risks (newer filing 2026-04-21)
- Removed:
- Reference to 'expected impacts of the U.S. government shutdown' in forward-looking statements (present in older filing 2025-10-21, removed in newer)
- Reference to 'U.S. government shutdown that began in October 2025' in conditions affecting global economy bullet point (older filing 2025-10-21)
- Parenthetical phrase '(including the impact of military conflicts)' from the economic/political factors bullet point (older filing 2025-10-21)
- Language about 'elections can result in significant political shifts and/or disruptions' (older filing 2025-10-21)
- Reference to 'Delays in National Institutes of Health ("NIH") funding related to the U.S. government shutdown that commenced in October 2025' (older filing 2025-10-21)
- Parenthetical note '(in this Report, references to products and services also includes software)' removed from growth depends on development bullet point (older filing 2025-10-21 had this; newer does not)
- Reworded:
- Annual report year changed from 'December 31, 2024' (older) to 'December 31, 2025' (newer)
- Quarterly period changed from 'three and nine-month periods ended September 26, 2025' (older) to 'three-month period ended March 27, 2026' (newer)
- Forward-looking statements list no longer includes 'expected impacts of the U.S. government shutdown' as a specific projection item (older filing 2025-10-21)
- AI language changed from 'Uncertainties with respect to the development, deployment and use of artificial intelligence' (older) to 'The development, deployment and use of artificial intelligence in our business and products, and uncertainties with respect thereto,' (newer)
- Economic/political factors bullet point reworded to remove specific reference to NIH funding delays and government shutdown, replacing with more general geopolitical language
- 'Global heath crises' (apparent typo in older) changed to 'Global health crises' (corrected in newer)
- Acquisitions risk bullet point now explicitly references 'Our acquisition of businesses (including our pending acquisition of Masimo Corporation)' versus older version that did not name Masimo
- Notes:
- The older filing text for Acquisitions, Divestitures and Investment Risks section appears truncated ('Dives' at end), so comparison at section end is incomplete
- Both filings reference forward-looking statements but the newer filing updates temporal context from 2024/2025 filings to 2025/2026 filings, which is consistent with normal quarterly progression
- The removal of government shutdown references reflects passage of time between filing dates (October 2025 filing vs. April 2026 filing)
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($237207) — 1 selling insider
Most recent open-market transaction: 2026-05-01. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DHR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 22 matched disclosures for DHR from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding DHR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 104,506,933
- Reported value $19,825,496,126
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DHR had 12,074,192 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DHR had 1.72% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.38 days to cover at the same settlement.
- Reported short interest (shares) 12,074,192
- Short interest (% of shares outstanding) 1.72%
- Prior settlement (shares) 10,096,457
- Reported change 19.59%
- Days to cover (reported) 1.38
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific
- Becton Dickinson (BDX)
- Abbott Diagnostics (ABT)
- Siemens Healthineers
- Roper Technologies (ROP)
- Xylem Inc. (XYL)
- PerkinElmer (PKI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DHR vs…
Danaher Corporation is found in…
Frequently asked questions
What does Danaher Corporation (DHR) do?
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through a diversified portfolio of science and technology-based businesses, focusing on life sciences, diagnostics, and environmental and applied solutions. Its products are used extensively in research, laboratory, and production environments globally.
What sector is Danaher Corporation (DHR) in?
Danaher Corporation (DHR) is classified in the Health Care sector. Its industry is Diversified life sciences, diagnostics, and industrial instrumentation. It trades on NYSE.
Does DHR pay a dividend?
Yes — Danaher Corporation (DHR) pays a dividend, with an indicated yield of about 0.49% (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Danaher Corporation's (DHR) competitors?
Notable peers of Danaher Corporation (DHR) include Thermo Fisher Scientific, Becton Dickinson, Abbott Diagnostics, Siemens Healthineers and Roper Technologies. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in DHR?
Yes — we hold 22 matched STOCK Act disclosures for DHR from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Danaher Corporation (DHR) overbought or oversold right now?
Danaher Corporation (DHR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 68, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DHR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.